Nrf2 Activator Derivatives for Oxidative Stress and Nerve Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's lack effective drugs to slow disease progression, and existing Nrf2 activators show promise but require further development for broader therapeutic applications.
Innovation Solution
Development of a new class of Nrf2 activators, specifically (E)-3-arylheterocyclylprop-2-enoic acid derivatives, which activate the Nrf2 signaling pathway to combat oxidative stress and enhance mitochondrial function, thereby protecting nerve cells and potentially treating neurodegenerative diseases, autoimmune diseases, diabetes, and other chronic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new Nrf2 activators are developed to treat neurodegenerative diseases, then therapeutic effectiveness is improved, but development complexity and time are increased
Solution Approach 1:
The patent segments the Nrf2 activator development into specific chemical series (compounds of Formula I) with defined structural parameters (R1-R11 substituents), allowing systematic exploration of structure-activity relationships to improve therapeutic effectiveness while managing development complexity through organized chemical space exploration
Solution Approach 2:
The patent develops compounds with multi-functional capabilities: activating Nrf2 signaling pathway, resisting oxidative stress, enhancing mitochondrial function, and protecting nerve cells. This universal approach allows a single compound class to address multiple aspects of neurodegenerative diseases simultaneously
2Reliability
If Nrf2 activators are used to resist oxidative stress and enhance mitochondrial function, then nerve cell protection is improved, but mechanism complexity is increased
Solution Approach 1:
The patent merges multiple protective mechanisms into a single Nrf2 activator compound: antioxidant defense through Nrf2 pathway activation, mitochondrial biogenesis enhancement, and anti-inflammatory effects. This consolidation achieves comprehensive nerve cell protection through one primary molecular target while coordinating multiple downstream protective pathways
3Reliability
If compounds with multiple substituents are synthesized to optimize Nrf2 activation, then biological activity is improved, but manufacturing complexity is increased
Solution Approach 1:
The patent applies local quality by defining specific substituent patterns at different positions (R1-R11) of the core heterocyclic structure, where each position can be independently optimized with specific functional groups to enhance Nrf2 activation activity while maintaining a manageable synthetic route through modular substitution strategies
Data Source
AI summary
The present application relates to the pharmaceutical use of a class of (E)-3-arylheterocyclyl prop-2-enoic acid derivatives. Such compounds are a class of new Nrf2 activators, which effectively activate Nrf2 signaling pathway to produce the effects of resisting oxidative stress, resisting neuritis, and enhancing mitochondrial function and biogenesis, thereby protecting nerve cells, and same can be used to treat neurodegenerative diseases and stroke. In addition, such new Nrf2 activators can also be used to treat autoimmune diseases, diabetes, nephropathy, and other chronic diseases.